Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719375 | 0.87 | ADORA3 (0.41) | ADORA3TLR7FPR2SCN9AKDM4E | |
| SCHEMBL718383 | 0.86 | LMNA (0.41) | ADORA3FPR2SCN9AKDM4EPKM | |
| SCHEMBL719539 | 0.86 | CA12 (0.47) | KDM4EPKML3MBTL1 | |
| SCHEMBL16035755 | 0.86 | KDM4E (0.40) | KDM4EPKML3MBTL1 | |
| SCHEMBL720191 | 0.84 | KDM4E (0.41) | ADORA3KDM4EPKML3MBTL1 | |
| SCHEMBL721162 | 0.84 | KDM4E (0.51) | ADORA3KDM4EPKML3MBTL1 | |
| SCHEMBL719484 | 0.83 | RAB9A (0.41) | KDM4EPKML3MBTL1 | |
| SCHEMBL16036947 | 0.83 | KDM4E (0.39) | KDM4EPKML3MBTL1 | |
| SCHEMBL16075405 | 0.82 | CHRNA7 (0.49) | ADORA3CHRNA7TLR7FPR2SCN9A | |
| SCHEMBL16047514 | 0.82 | KCNH2 (0.42) | FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA CROP PROTECTION LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA CROP PROTECTION LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010125332-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010092339-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | DPYD, DHODH, TYMP | ADORA3 445/4885CHRNA7 4063/4885TLR7 4423/4885 |
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | TYMS, DHFR, UNG | ADORA3 2014/4885CHRNA7 4860/4885TLR7 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.